What factors drove the changes in Nephros's revenue and profit?

Did Nephros beat or miss consensus estimates last quarter?

What does Nephros do and what are its main business segments?

What were the key takeaways from Nephros's earnings call?

What is the market's earnings forecast for Nephros next quarter?

What is Nephros's gross profit margin?

What were the key takeaways from Nephros’s earnings call?

What guidance did Nephros's management provide for the next earnings period?

- **Revenue Growth**: Q3 2025 revenue of $4.8 million (+35% YoY) driven by programmatic business and service revenue.
- **Profitability**: 5 consecutive quarters of profit with net income $337,000 (+84% YoY).
- **New Markets**: PFAS solution targeting municipalities and labs, expanding into dental and government facilities.
- **Operational Strength**: 1,650 active sites, $5.2 million cash, zero debt.
- **Strategic Initiatives**: Filtration Installation Program boosting reorder rates, tariff mitigation strategies.

**【CEO Summary Section】**
- Reported Q3 2025 revenue of $4.8 million, a 35% year-over-year increase, driven by programmatic business and service revenue growth.
- Highlighted 5 consecutive quarters of profitability and a record 1,650 active customer sites.
- Emphasized the Filtration Installation Program as a growth driver, with reorder rates improving customer loyalty and engagement.
- Announced the PFAS removal solution entering the field, targeting new markets like municipalities and labs.
- Discussed expansion into dental, municipal, and government facilities, supported by operational discipline.

**【CFO Financial Commentary】**
- Gross margins remained stable at 61%, despite higher inventory handling expenses offset by reduced reserves.
- R&D expenses increased to $338,000 (vs. $188,000 in Q3 2024) due to employee bonuses and headcount growth.
- SG&A expenses rose 30% to $2.2 million, driven by sales commissions and bonus accruals.
- Net income reached $337,000, up 84% YoY, with adjusted EBITDA of $418,000.
- Cash balance increased to $5.2 million, maintaining a debt-free position.

**【Q&A Key Highlights】**
- **PFAS Solution**: CEO Robert Banks detailed PFAS as a 'door opener' for new markets, though early-stage, with potential to address nanoplastics and regulatory compliance.
- **Margins and Tariffs**: CFO Judy noted tariffs impacting COGS but manageable through price increases and inventory management, targeting 60%+ gross margins.
- **Service Revenue**: Defined as filter installations and replacements, growing alongside programmatic business.
- **Market Expansion**: CEO highlighted penetration into non-hospital sectors like correctional facilities and schools, leveraging shared risk profiles with healthcare networks.
- **Legionella Impact**: Acknowledged increased awareness from publicity, driving customer education and water safety programs without direct revenue impact.


Nephros, Inc. (NEPH) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 2025 revenue up 36% YoY to $4.4 million; H1 2025 revenue up 37% to $9.3 million.
- **Profitability**: Q2 net income $237,000 (vs. loss in 2024); H1 net income $795,000.
- **Gross Margin Expansion**: 63% in Q2 (up 4 pts YoY), driven by cost reductions.
- **Key Initiatives**: Filter tracking app adoption, installation program success, and sales expansion into new verticals.
- **Future Growth**: Targeting dental, government, and municipal markets with new products like S100 microfilter.

**【CEO Summary Section】**
- Q2 2025 net revenue reached $4.4 million, up 36% year-over-year, marking the third consecutive quarter of profitability.
- Trailing 12-month revenue grew from $13.8 million to $16.7 million, with 400+ new active customer sites added over 2 years.
- First half 2025 revenue hit $9.3 million, a 37% increase vs. 2024, driven by programmatic business (40% CAGR) and record programmatic sales despite lower emergency volumes.
- Key initiatives: installation program (accelerated reorder rates), filter tracking app adoption (thousands of filters tracked), and sales expansion into non-healthcare verticals (dental, government, municipal).
- Retention rate highest in 6 quarters, serving over 1,600 active customer sites.
- Future focus: underserved verticals, new product launches (S100 microfilter, 20-inch HydraGuard), and operational discipline to protect profitability.

**【CFO Financial Commentary】**
- Q2 2025 gross margin improved to 63% (vs. 59% in Q2 2024), driven by reduced shipping costs and inventory adjustments.
- R&D expenses rose to $311,000 (from $254,000) due to headcount expansion.
- SG&A expenses increased 13% to $2.2 million, driven by higher sales commissions, bonuses, and stock compensation.
- Positive net income of $237,000 vs. $289,000 loss in Q2 2024; adjusted EBITDA of $355,000 vs. $133,000 loss.
- H1 2025 net income of $795,000 vs. $458,000 loss; cash balance $5.1 million (up from $3.8 million at year-end 2024).

**【Q&A Key Highlights】**
- **Growth Drivers**: CEO attributes success to filter tracking app (visibility), service programs (filter replacements), and sales team execution. App adoption enabled proactive customer engagement and reorder rates.
- **Sales Force Expansion**: Current sales team capacity is a constraint. Company plans to add junior associates to maintain customer retention while senior reps pursue new verticals (dental, government, municipal). Expansion will focus on education about biological water safety risks.

Nephros, Inc. (NEPH) Q2 2025 Earnings Call Transcript

- **Revenue Resilience**: Full-year revenue held steady at $14.2 million, with Q4 '24 sales up 19% YoY, driven by programmatic growth and new customer additions.
- **Innovation Payoff**: The 20-inch HydraGuard UltraFilter and digital tracking tool are key growth drivers, with new customer sites contributing $1.9 million in 2024.
- **Profitability Breakthrough**: First-ever quarterly net income in Q3 '24 and full-year profit of $74,000 mark a shift to sustainable profitability.
- **Gross Margin Expansion**: 62% full-year gross margin (vs. 59% in 2023) reflects improved supplier terms and operational efficiency.
- **Cash Strength**: $3.8 million in cash at year-end and positive Q4 operating cash flow highlight strong liquidity.


**【CEO Summary Section】**
- **Revenue Performance**: Full-year 2024 net revenue remained steady at $14.2 million, with programmatic business growing 9% despite a decline in emergency response sales. Q4 '24 net revenue rose 19% YoY to $3.9 million, driven by programmatic growth.
- **New Product Launch**: Introduced the 20-inch HydraGuard UltraFilter, targeting higher flow rate applications in sterile processing, laboratories, and manufacturing. This product aligns with the ANSI/AAMI ST108 standard, enhancing compliance and patient safety.
- **Customer Expansion**: Added 599 new customer sites in 2024, contributing $1.9 million in sales (13% of annual revenue) and stabilizing same-site sales through a digital tracking tool.
- **Profitability Milestone**: Achieved first-ever quarterly net income in Q3 '24, with full-year net income of $74,000 vs. a $1.6 million loss in 2023.

**【CFO Financial Commentary】**
- **Gross Margin Improvement**: Q4 '24 gross margin rose to 64% (vs. 62% in Q4 '23), and full-year margin increased to 62% (vs. 59% in 2023), driven by favorable supplier terms.
- **Cost Management**: SG&A expenses decreased 15% YoY to $7.7 million, with reductions in bonuses, commissions, and professional fees.
- **Cash Flow**: Q4 '24 operating cash flow was $1.3 million (vs. -$200,000 in Q4 '23), ending the year with $3.8 million in cash.
- **R&D Investment**: Full-year R&D expenses rose 4% to $906,000, supporting product innovation.

**【Q&A Highlights】**
- **HydraGuard Market Potential**: CEO estimates the new product will contribute significantly to programmatic growth, with a pipeline of opportunities in sterile processing and beyond healthcare.
- **Digital Tool Impact**: A digital tracking app launched mid-Q4 '24 has improved visibility into same-site sales, reducing churn and driving programmatic growth.
- **Cost Efficiency**: CFO notes the company is operationally lean, with plans to invest selectively in R&D and marketing as revenue grows.
- **Macroeconomic Resilience**: CEO highlights the healthcare sector's relative insulation from macroeconomic volatility, driven by patient safety needs rather than economic cycles.


NEPH

NEPH fundamentals

Earnings Call

You can ask Aime